Challenge Testing of Kraig Biocraft Laboratories’ Disease Resistant Silkworms Underway
Kraig Biocraft Laboratories (OTCQB: KBLB) has initiated challenge testing for its immunity-enhanced silkworms, designed to combat devastating viral and fungal infections impacting global silk production. With up to 50% of losses attributed to a specific virus affecting 75% of producers, Kraig Labs aims to license these disease-resistant silkworms to mitigate significant economic losses in the $14B silk industry. Successful testing could lead to commercial availability, further advancing their commitment to cost-effective and environmentally sustainable silk solutions.
- Kraig Labs has developed immunity-enhanced silkworms that can potentially prevent the loss of silk production due to viral infections.
- The initiative targets a significant issue in the silk industry, which could lead to new licensing opportunities.
- The company's strategic focus on genetic engineering technologies for commercial applications aligns with market needs.
- None.
Immunity enhanced silkworms provide licensing opportunities into the broader
ANN ARBOR, Mich., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has begun challenge testing on of its immunity enhanced silkworms. These silkworms were developed by Kraig Labs to combat viral and fungal infections that result in significant losses in global silk production.
As much as
By adapting its genetic engineering technologies, used to produce recombinant spider silk, Kraig Labs has developed multiple lines of silkworms that incorporate a genetic defense against this virus and other prominent silkworm diseases. As designed, the silkworm's immune system will target and eliminate any copy of the virus DNA, preventing the spread of infection and loss.
Having built a sizeable colony of these immunity-enhanced silkworms, the Company is now undergoing challenge testing at a controlled offsite test location. This remote offsite location was selected to prevent the potential introduction and spread of the virus into Kraig Labs R&D headquarters.
These new disease-resistant silkworms are intended for licensing into the global market for mundane silks to combat key pathogenic viruses and fungi. The Company expects to make these lines of resilient silkworms available for commercial licensing upon the conclusion of successful challenge testing and intends to incorporate this technology into all of its lines of spider silk transgenics.
“With testing now underway, we are excited to see the potential that these new silkworm strains can bring to the broader sericulture industry,” said the Company’s COO, Jon Rice. “Combating these silkworm diseases is an industry-wide challenge. Bringing licensable, immunity-enhanced silkworms to the global silk market advances our business model and aligns with our core focus in commercializing cost-effective and environmentally responsible recombinant spider silk.”
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
1 From New Analysis from Global Industry Analysts Reveals Steady Growth for Silk, with the Market to Reach
FAQ
What are immunity-enhanced silkworms from Kraig Labs?
What economic impact do viral infections have on silk production?
When will Kraig Labs make the new silkworms available for commercial licensing?
How does Kraig Labs' technology contribute to the silk market?
